Organic compounds -- part of the class 532-570 series – Organic compounds – Carbohydrates or derivatives
Reexamination Certificate
2011-06-14
2011-06-14
Chong, Kimberly (Department: 1635)
Organic compounds -- part of the class 532-570 series
Organic compounds
Carbohydrates or derivatives
C536S024100, C536S024310, C435S006120, C435S325000, C435S375000, C514S04400A
Reexamination Certificate
active
07960541
ABSTRACT:
An antisense molecule capable of binding to a selected target site to induce exon skipping in the dystrophin gene, as set forth in SEQ ID NO: 1 to 202.
REFERENCES:
patent: 5034506 (1991-07-01), Summerton et al.
patent: 5142047 (1992-08-01), Summerton et al.
patent: 5149797 (1992-09-01), Pederson et al.
patent: 5166315 (1992-11-01), Summerton et al.
patent: 5185444 (1993-02-01), Summerton et al.
patent: 5217866 (1993-06-01), Summerton et al.
patent: 5506337 (1996-04-01), Summerton et al.
patent: 5521063 (1996-05-01), Summerton et al.
patent: 5627274 (1997-05-01), Kole et al.
patent: 5665593 (1997-09-01), Kole et al.
patent: 5892023 (1999-04-01), Pirotzky et al.
patent: 6210892 (2001-04-01), Bennett et al.
patent: 6656732 (2003-12-01), Bennett et al.
patent: 6784291 (2004-08-01), Iversen et al.
patent: 7070807 (2006-07-01), Mixson
patent: 7163695 (2007-01-01), Mixson
patent: 7250289 (2007-07-01), Zhou
patent: 7468418 (2008-12-01), Iversen et al.
patent: 7807816 (2010-10-01), Wilton et al.
patent: 2003/0224353 (2003-12-01), Stein et al.
patent: 2004/0248833 (2004-12-01), Emanuele et al.
patent: 2007/0082861 (2007-04-01), Matsuo et al.
patent: 2010/0130591 (2010-05-01), Sazani et al.
patent: 2011/0015253 (2011-01-01), Wilton et al.
patent: 2011/0015258 (2011-01-01), Wilton et al.
patent: 780517 (2001-11-01), None
patent: 2003284638 (2004-06-01), None
patent: 2 507 125 (2004-06-01), None
patent: 1 191 097 (2002-03-01), None
patent: 1 766 010 (2007-03-01), None
patent: WO 94/02595 (1994-02-01), None
patent: WO 96/10391 (1996-04-01), None
patent: WO 96/10392 (1996-04-01), None
patent: WO 97/30067 (1997-08-01), None
patent: WO 97/34638 (1997-09-01), None
patent: WO 00/44897 (2000-08-01), None
patent: WO 01/49775 (2001-07-01), None
patent: WO 01/83740 (2001-11-01), None
patent: WO 02/024906 (2002-03-01), None
patent: WO 2004/048570 (2004-06-01), None
patent: WO 2004/083432 (2004-09-01), None
patent: WO 2004/083446 (2004-09-01), None
patent: WO 2006/000057 (2006-01-01), None
Aartsma-Rus et al., “Antisense-Induced Multiexon Skipping for Duchenne Muscular Dystrophy Makes More Sense,”Am. J. Hum. Genet. 74:83-92, 2004.
Aartsma-Rus et al., “Therapeutic antisense-induced exon skipping in cultured muscle cells from six different DMD patients,”Human Molecular Genetics 12(8):907-914, 2003.
Aartsma-Rus et al., “Targeted exon skipping as a potential gene correction therapy for Duchenne muscular dystrophy,”Neuromuscular Disorders 12:S71-S77, 2002.
Abbs et al., “A convenient multiplex PCR system for the detection of dystrophin gene deletions: a comparative analysis with cDNA hybridisation shows mistyping by both methods,”J. Med. Genet. 28:304-311, 1991.
Agrawal et al., “Oligodeoxynucleoside phosphoramidates and phosphorothioates as inhibitors of human immunodeficiency virus,”Proc. Natl. Acad. Sci. USA 85:7079-7083, Oct. 1988.
Akhtar et al., “Cellular uptake and intracellular fate of antisense oligonucleotides,”Trends in Cell Biology 2:139-144, May 1992.
Akhtar, Saghir, (ed.),Delivery Strategies for Antisense Oligonucleotide Therapeutics, CRC Press, Boca Raton, Florida, 1995.
Anderson, “Human Gene Therapy,”Science 256:808-813, May 8, 1992.
Berge et al., “Pharmaceutical Salts,”Journal of Pharmaceutical Sciences 66(1):1-19, Jan. 1977.
Brown et al., “Dystrophic phenotype induced in vitro by antibody blockade of muscle α-dystroglycan-laminin interaction,”Journal of Cell Science 112:209-216, 1999.
Collins et al., “Duchenne's muscular dystrophy: animal models used to investigate pathogenesis and develop therapeutic strategies,”International Journal of Experimental Pathology 84:165-172, 2003.
De Angelis et al., “Chimeric snRNA molecules carrying antisense sequences against the splice junctions of exon 51 of the dystrophin pre-mRNA induce exon skipping and restoration of a dystrophin synthesis in Δ48-50 DMD cells,”Proc. Natl. Acad. Sci. USA 99(14):9456-9461, Jul. 9, 2002.
DelloRusso et al., “Functional correction of adultmdxmouse muscle using gutted adenoviral vectors expressing full-length dystrophin,”Proc. Natl. Acad. Sci. USA 99(20):12979-12984, Oct. 2002.
Dirksen et al., “Mapping the SF2/ASF Binding Sites in the Bovine Growth Hormone Exonic Splicing Enhancer,”The Journal of Biological Chemistry 275(37):29170-29177, 2000.
Dunckley et al., “Modification of splicing in the dystrophin gene in culturedMdxmuscle cells by antisense oligoribonucleotides,”Human Molecular Genetics 5(1):1083-1090, 1995.
Dunckley et al., “Modulation of Splicing in theDMDGene by Antisense Oligoribonucleotides,”Nucleosides&Nucleotides 16(7-9):1665-1668, 1997.
Errington et al., “Target selection for antisense oligonucleotide induced exon skipping in the dystrophin gene,”The Journal of Gene Medicine 5:518-527, 2003.
Friedmann, “Progress Toward Human Gene Therapy,”Science 244:1275-1281, Jun. 16, 1989.
Gebski et al., “Morpholino antisense oligonucleotide induced dystrophin exon 23 skipping inmdxmouse muscle,”Human Molecular Genetics 12(15):1801-1811, 2003.
Giles et al., “Antisense Morpholino Oligonucleotide Analog Induces Missplicing of C-mycmRNA,”Antisense&Nucleic Acid Drug Development 9:213-220, 1999.
Gennaro, Alfonso R., (ed.),Remington 's Pharmaceutical Studies, 18thEdition, Mack Publishing, Co., Eastern, PA. 1990.
Harel-Bellan et al., “Specific Inhibition of c-mycProtein Biosynthesis Using an Antisense Synthetic Deoxy-Oligonucleotide in Human T Lymphocytes,”The Journal of Immunology 140(7):2431-2435, Apr. 1, 1988.
Hussey et al., “Analysis of five Duchenne muscular dystrophy exons and gender determination using conventional duplex polymerase chain reaction on single cells,”Molecular Human Reproduction 5(11):1089-1094, 1999.
International Search Report for International Application No. PCT/US01/14410, mailed Mar. 6, 2002, 5 pages.
Karras et al., “Deletion of Individual Exons and Induction of Soluble Murine Interleukin-5 Receptor-α Chain Expression through Antisense Oligonucleotide-Mediated Redirection of Pre-mRNA Splicing,”Molecular Pharmacology 58:380-387, 2000.
Liu et al., “Identification of functional exonic splicing enhancer motifs recognized by individual SR proteins,”Genes&Development 12:1998-2012, 1998.
Lu et al., “Massive Idiosyncratic Exon Skipping Corrects the Nonsense Mutation in Dystrophic Mouse Muscle and Produces Functional Revertant Fibers by Clonal Expansion,”The Journal of Cell Biology 148(5):985-995, Mar. 6, 2000.
Lu et al., “Functional amounts of dystrophin produced by skipping the mutated exon in themdxdystrophic mouse,”Nature Medicine9(8):1009-1014, Aug. 2003.
Mann et al., “Antisense-induced exon skipping and synthesis of dystrophin in themdxmouse,”Proc. Natl. Acad. Sci. USA 98(1):42-47, Jan. 2, 2001.
Mann et al., “Improved antisense oligonucleotide induced exon skipping in themdxmouse model of muscular dystrophy,”The Journal of Gene Medicine 4:644-654, 2002.
Matsuo et al., “Exon Skipping during Splicing of Dystrophin mRNA Precursor due to an intraexon Deletion in the Dystrophin Gene of Duchenne Muscular Dystrophy Kobe,”J. Clin. Invest. 87:2127-2131, Jun. 1991.
Matsuo, “Duchenne/Becker muscular dystrophy: from molecular diagnosis to gene therapy,”Brain&Development 18:167-172, 1996.
Matsuo, “Duchenne and Becker Muscular Dystrophy: From Gene Diagnosis to Molecular Therapy,”IUBMB Life 53:147-152, 2002.
Monaco et al., “An Explanation for the Phenotypic Differences between Patients Bearing Partial Deletions of the DMD Locus,”Genomics 2:90-95, 1988.
Patentee's Response to European Patent Application No. 05076770.6, dated Jul. 28, 2006, 4 pages.
Pramono et al., “Induction of Exon Skipping of the Dystrophin Transcript in Lymphoblastoid Cells by Transfe
Fletcher Sue
McClorey Graham
Wilton Stephen Donald
Chong Kimberly
Seed IP Law Group PLLC
The University of Western Australia
LandOfFree
Antisense oligonucleotides for inducing exon skipping and... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Antisense oligonucleotides for inducing exon skipping and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Antisense oligonucleotides for inducing exon skipping and... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2631017